Related references
Note: Only part of the references are listed.Unboosted Atazanavir for Treatment of HIV Infection
Emanuele Focà et al.
DRUGS (2012)
Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
Eric S. Daar et al.
ANNALS OF INTERNAL MEDICINE (2011)
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients
Stefano Bonora et al.
ANTIVIRAL THERAPY (2011)
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy
Juliette Pavie et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
Kathleen E. Squires et al.
AIDS (2010)
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
Jade Ghosn et al.
ANTIVIRAL THERAPY (2010)
Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study
R. Giuntini et al.
HIV MEDICINE (2010)
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
The genotypic inhibitory quotient - A predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients
Caroline Solas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Population Pharmacokinetics of Atazanavir in Human Immunodeficiency Virus-Infected Patients
Caroline Solas et al.
THERAPEUTIC DRUG MONITORING (2008)
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice
Jose Molto et al.
THERAPEUTIC DRUG MONITORING (2007)
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice
R. M. M. Cleijsen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
Sara Colombo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Ways to fit a PK model with some data below the quantification limit
SL Beal
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check
Y Yano et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable
GL Drusano et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Share Paper
